Page last updated: 2024-11-08

cefamandole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID456255
CHEMBL ID1146
CHEBI ID3480
SCHEMBL ID37287
MeSH IDM0003716

Synonyms (71)

Synonym
(6r,7r)-7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
AC-1294
BRD-K27130738-236-03-4
(6r,7r)-7-{[(2r)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
PRESTWICK2_000747
BSPBIO_000734
PRESTWICK3_000747
cefadole
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-, 6r,7r)-
(6r,7r)-7-[[(2r)-2-hydroxy-2-phenyl-acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefamandole
C06879
34444-01-4
cephadole
(6r,7r)-7-{[(2r)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cephamandole
l-cefamandole
DB01326
(6r,7r)-7-(r)-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid
D02344
cefamandole (usan/inn)
BPBIO1_000808
compound 83405
brn 0598510
cefamandol [inn-spanish]
cefamandol
mancef
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7beta(r*)))-
7-d-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid
kefamandol
einecs 252-030-0
cefamandolum [inn-latin]
PRESTWICK1_000747
SPBIO_002673
PRESTWICK0_000747
j01dc03
compound-83405
CHEMBL1146
cefamandolum
7beta-[(2r)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
CHEBI:3480 ,
7-[(2-hydroxy-2-phenylacetyl)amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
bdbm50350468
5ckp8c2lli ,
cefamandole [usan:inn:ban]
unii-5ckp8c2lli
EPITOPE ID:141490
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((hydroxyphenylacetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6.alpha.,7.beta.(r*)))-
cefamandole [mi]
cefamandole [mart.]
(6r,7r)-7-(r)-mandelamido-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-carboxylic acid
cefamandole [usan]
cefamandole [vandf]
cefamandole [who-dd]
cefamandole [inn]
SCHEMBL37287
CS-4724
W-106736
cefamandole, antibiotic for culture media use only
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-, (6r,7r)-
OLVCFLKTBJRLHI-AXAPSJFSSA-N
HY-B1128
DTXSID7022750
AKOS025401365
(6r,7r)-7-[(2r)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-((r)-2-hydroxy-2-phenylacetamido)-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
free form'
Q2601530
(6r,7r)-7-((r)-2-hydroxy-2-phenylacetamido)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
EN300-19734690
gtpl12210

Research Excerpts

Overview

Cefamandole is a second-generation cephalosporin with a high level of activity against common aerobic pathogens, both Gram-positive and Gram-negative. It is a safe, effective and well-tolerated agent in the treatment of skin and soft tissue infections of adult patients.

ExcerptReferenceRelevance
"Cefamandole is a second-generation cephalosporin with a high level of activity against common aerobic pathogens, both Gram-positive and Gram-negative. "( Cefamandole against Bacteroides fragilis.
McAllister, TA, 1980
)
3.15
"Cefamandole nafate is a new cephalosporin antibiotic with an antimicrobial spectrum similar to cephalothin with increased activity against Escherichia coli, Proteus spp., Enterobacter spp., and Haemophilus influenzae."( Cefamandole treatment of pulmonary infection caused by gram-negative rods.
Mandell, GL, 1980
)
2.43
"Cefamandole would seem to be a safe and efficacious drug, for the treatment of serious bone and joint infections due to a wide variety of gram-positive and gram-negative microorganisms."( Cefamandole in the treatment of serious bone and joint diseases.
Levine, LR, 1980
)
2.43
"Cefamandole nafate is a safe, effective and well-tolerated agent in the treatment of skin and soft tissue infections of adult patients caused by susceptible organisms."( Cefamandole in the treatment of soft tissue infections.
Bermúdez, RH; Lugo-Velázquez, A; Quiñones-Soto, R; Ramírez-Ronda, CH, 1982
)
2.43
"Cefamandole appears to be a reasonable alternative in the initial treatment of skeletal infections in children, but need to be administered every 4 h to maintain suprainhibitory serum levels between doses."( Pharmacology, Safety, and efficacy of cefamandole in childhood infections.
Dajani, AS; Maurer, MJ; Thirumoorthi, MC; Vincent, CV, 1981
)
1.26
"Cefamandole is a new cephalosporin active against non beta-lactamase producing enterobacteria, at lower concentrations (mean of MIC: 0.79 mcg/ml) than those of cefalothin taken as a reference amongst current cephalosporins (mean of MIC: 6.84 mcg/ml). "( [Activity of cefamandole against enterobacteria resistant to cephalosporins (author's transl)].
Gailliard, MC; Kazmierczak, A; Labia, R; Portier, H; Siebor, E, 1979
)
2.07
"Cefamandole nafate is a derivative of 7-aminocephalosporanic acid which has been shown to have good in vitro activity against aerobes traditionally susceptible to cephalosporins as well as many anaerobes, including B. "( Treatment of obstetric and gynecologic infections with cefamandole.
Cunningham, FG; Gilstrap, LC; Kappus, SS, 1979
)
1.95
"Cefamandole appears to be an effective and preferable prophylactic antibiotic for use during cardiac surgery."( Comparative study of cefamandole versus cephalothin as antibiotic prophylaxis for open heart surgery.
Koltai, C; Lukács, L; Mészáros, R; Windisch, M, 1986
)
1.31

Effects

ExcerptReferenceRelevance
"Cefamandole nafate has been shown to have good in vitro activity against a wide spectrum of aerobic and anaerobic pathogens frequently isolated from women with obstetrical and gynecological infections. "( Cefamandole for treatment of obstetrical and gynecological infections.
Cunningham, FG; Gilstrap, LC; Kappus, SS, 1980
)
3.15

Actions

ExcerptReferenceRelevance
"The cefamandole group had a lower rate of Gram-negative organisms (23% versus 44%, p less than 0.01)."( Two-day cefamandole versus five-day cephazolin prophylaxis in 965 total hip replacements. Report of a multicentre double blind randomised trial.
Acar, JF; Doyon, F; Evrard, J; Flamant, R; Mazas, F; Salord, JC, 1988
)
1.19

Treatment

Cefamandole treatment in 112 patients resulted in an 8.9 per cent postoperative infection rate compared with 16.3 per cent in 141 matched control patients. Treatment with cefam andole nafate, which had not been used previously in Y enterocolitica lung disease, resulted in cure.

ExcerptReferenceRelevance
"Cefamandole treated bacteria were more susceptible to the rat serum bactericidal activity then control bacteria."( [Bactericidal activity of the serum against Staphylococcus aureus grown in the presence of subinhibitory doses of cefamandole and gentamicin].
Andreana, A; Dilillo, M; Perna, P; Ruggiero, G; Utili, R, 1984
)
1.2
"Cefamandole treatment in 112 patients resulted in an 8.9 per cent postoperative infection rate compared with 16.3 per cent in 141 matched control patients."( Cefamandole preparation for colonic surgery.
Eisenberg, HW,
)
2.3
"Treatment with cefamandole nafate, which had not been used previously in Y enterocolitica lung disease, resulted in cure."( Yersinia enterocolitica lung infection.
Atkins, RR; Bigler, RD; Wing, EJ, 1981
)
0.6

Toxicity

ExcerptReferenceRelevance
" Ceftazidime is as safe and effective as cefamandole for the treatment of pneumonia due to a variety of Gram-positive and Gram-negative pathogens."( Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia.
Lifland, PW; Nolen, T; Palumbo, JA; Schleupner, CJ; Yangco, BG, 1986
)
0.76
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

The aim of the present study was to establish the pharmacokinetic parameters of cefamandole and ceftazidime for patients receiving these cephalosporins by continuous infusion. The pharmacodynamic and nephrotoxic effects were investigated.

ExcerptReferenceRelevance
"A review is given on the pharmacokinetic characteristics of some cephalosporin antibiotics."( On the pharmacokinetics of cephalosporin antibiotics.
Andersson, KE, 1978
)
0.26
"The pharmacokinetic characteristics of cefamandole were determined after intravenous administration of a 1-Gm dose to 10 subjects with normal renal function, 10 patients with stabilized renal failure, and five chronic nephritic patients included in a intermittent hemodialysis program."( Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
Brogard, JM; Grudet, O; Kopferschmitt, J; Lavillaureix, J; Spach, MO, 1979
)
1.97
" No significant differences were observed in plasma-renal pharmacokinetic parameters between single and multiple doses of ceforanide."( Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.
Glick, A; Hottendorf, GH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1979
)
0.26
"The pharmacokinetic properties of cefamandole were determined and compared with the properties of other cephalosporin agents."( Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds.
Neu, HC, 1978
)
0.81
" Half-life and distribution volume of this antibiotic and the glomerular filtration rate (GFR) were then measured."( [Cefamandol: pharmacokinetics with normal and impaired renal function (author's transl)].
Höffler, D; Moecke, D; Sassmann, M, 1978
)
0.26
" A pharmacokinetic study was performed on blood and resection chips collected at regular intervals."( [A pharmacokinetic study of diffusion in adenomatous prostatic tissue of an intravenous bolus of cefamandole].
Astier, L; Billebaud, T; Boccon-Gibod, L; Rutkowski, A, 1990
)
0.5
" Using pharmacokinetic parameters of the plasma concentrations in vivo and those of the Hill equation the corresponding time course of ER was calculated and by integration with respect to time (0tERdt), an estimate was obtained of the effect on bacteria."( Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.
Brus-Weijer, L; Krul, AM; Mattie, H; van Dokkum, AM; van Strijen, E, 1990
)
0.28
"The authors have explored the effects of cefonicid on the steady-state pharmacokinetics of a new sustained-release theophylline formulation in 12 adult patients suffering from chronic obstructive lung disease, by comparing the pharmacokinetic data obtained following four days of medication with theophylline alone with those found at the end of seven days of combined treatment with the same theophylline preparation plus cefonicid."( The effects of cefonicid on the pharmacokinetics of a once-a-day theophylline formulation.
Cazzola, M; D'Amato, G; Lobefalo, G; Lupis, F; Martucci, P; Vanacore, L, 1989
)
0.28
" Kinetic findings demonstrated a similar half-life for cefonicid in tissues and in serum."( Pharmacokinetics of cefonicid in serum and its penetration into lung tissue, bronchial mucosa and pleura.
Besa, G; Broccali, G; Furlan, G; Gusmitta, A, 1989
)
0.28
" Model-dependent and noncompartmental pharmacokinetic parameters were calculated and found to be congruous; noncompartmental data are reported."( Effect of age and renal function on cefonicid pharmacokinetics.
Ackerman, BH; Kearns, GL; Manning, JT; Monson, TP; Trang, JM; Underwood, FL, 1989
)
0.28
"kg-1 gave serum concentrations well within the therapeutic range for susceptible bacteria, and that its pharmacokinetic properties allow single daily doses to be used to treat infections in children."( Pharmacokinetics of cefonicid in children.
D'Elia, R; Furlanut, M; Pasinelli, F; Riva, E, 1989
)
0.28
" Several factors, including blood loss, fluid redistribution, and changes in renal blood flow may alter the pharmacokinetic disposition of the antibiotic."( Altered pharmacokinetics of antibiotics during vascular surgery.
Carver, M; Goldstone, J; Guglielmo, BJ; Rodondi, LC; Salazar, TA; Stoney, RJ, 1989
)
0.28
"The description of the relationship between different responses measured simultaneously in the same subject is commonly described in terms of specific pharmacokinetic models such as linear compartmental models."( Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.
Veng-Pedersen, P, 1988
)
0.27
" A compartment-independent pharmacokinetic analysis showed that MTT was rapidly removed from the plasma of normal subjects, but that peak concentrations of MTT were nearly three times greater and persisted for 48 hr in patients with renal failure."( Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function.
Aronoff, GR; Black, HR; Obermeyer, BD; Wolen, RL, 1986
)
0.54
"A pharmacokinetic model and distributional clearance terms to describe bidirectional peritoneal transfer were used to examine cefamandole pharmacokinetics in five uninfected patients with end-stage renal disease who were receiving continuous ambulatory peritoneal dialysis."( Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis.
Apicella, MA; Janicke, DM; Jusko, WJ; Morse, GD; Walshe, JJ, 1986
)
0.48
" To determine the in vivo pharmacokinetic significance of these observations, the pharmacokinetics of both total and unbound (non-protein-bound) cefonicid was studied in six volunteers after a single intravenous dose of 30 mg/kg."( Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.
Dudley, MN; Nightingale, CH; Quintiliani, R; Shyu, WC, 1986
)
0.27
" cefonicid dose produced high and prolonged plasma concentrations with a longer half-life than obtained with commonly used cephalosporins."( Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans.
Fillastre, JP; Fourtillan, JB; Humbert, G; Lefebvre, MA; Leroy, A; Ramis, N; Reumont, G,
)
0.13
"Knowledge of important pharmacokinetic parameters of a drug, such as its half-life in plasma and its distribution and body clearance, is helpful in understanding the time course of the plasma concentration of a drug as a function of dosage."( An overview of pharmacokinetics.
Cutler, RE,
)
0.13
" The pharmacokinetic disposition of the drug was examined in patients with various degrees of renal dysfunction and who were receiving hemodialysis."( Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.
Alexander, DP; Barriere, SL; Conte, JE; Gambertoglio, JG; Stagg, RJ,
)
0.13
" Ceforanide half-life varied with the ages of the patients: in 1- to 2-year-old children, in half-life was significantly shorter (1."( Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.
Bawdon, RE; Buckley, JA; Dajani, AS; Pfeffer, M; Smyth, RD; Thirumoorthi, MC; Van Harken, DR, 1982
)
0.26
"The pharmacokinetic of ceforanide, a new parenteral cephalosporin antibiotic, were examined at intravenous and intramuscular doses of 250, 500, and 1,000 mg in healthy male volunteers."( Pharmacokinetics of ceforanide.
Ghezzi, A; La Rosa, F; Pfeffer, M; Prenna, M; Ripa, S, 1982
)
0.26
"This study determined the pharmacokinetic disposition of cefonicid."( Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.
Barriere, SL; Conte, JE; Gambertoglio, JG; Hatheway, GJ; Lin, ET, 1982
)
0.26
" The antibiotic half-life was 34-37 minutes."( [Pharmacokinetics of cefamandole in rabbits].
Bobrov, VI; Iakovlev, VP; Klimova, VS; Nazarova, OI; Skala, LZ, 1982
)
0.58
" Pharmacokinetic properties were determined in rats (100 mg/kg), rabbits (30 mg/kg), dogs (25 mg/kg), and humans (2 g or 30 mg/kg) and compared with equivalent single doses of cefazolin."( Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
Hottendorf, GH; Lee, FH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1980
)
0.26
" The plasma half-life (T 1/2) of the drug was 19."( Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
Berman, SJ; Boughton, WH; Hess, JR; Musgrave, JE; Siemsen, AM; Sugihara, JG; Wong, EG, 1980
)
0.26
" These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored."( Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
Counter, FT; Draheim, SE; Eudaly, JA; Kasher, JS; Pike, AJ; Ternansky, RJ, 1993
)
0.29
"The pharmacodynamic and nephrotoxic effects of cefamandole were investigated."( Some pharmacodynamic and biochemical aspects of cefamandole.
el-Komy, AA; el-Sayed, MG; Hafez, MH; Hassanin, MR; Mohamed, A, 1997
)
0.81
" No changes in elimination half-life relative to a normal population occurred with cefuroxime, cefotiam, and ampicillin."( Pharmacokinetics of antibiotic prophylaxis in major orthopedic surgery and blood-saving techniques.
Dehne, MG; Hempelmann, G; Mühling, J; Nopens, H; Sablotzki, A, 2001
)
0.31
" The aim of the present study was to establish the pharmacokinetic parameters of cefamandole and ceftazidime for patients receiving these cephalosporins by continuous infusion."( Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.
Berkhout, J; Mattie, H; van de Klundert, JA; van den Broek, PJ; Visser, LG, 2003
)
0.84
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The terminal half-life of ceftazidime in blister fluid (2."( The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.
Andrews, JM; Armstrong, GC; Brown, RM; Wise, ER, 1981
)
0.5

Compound-Compound Interactions

The new semisynthetic aminoglycoside netilmicin may adversely affect the nephrotoxicity of the new antibiotics. We gave ampicillin, carbenicillin, methicillin,. cefamandole, and clindamycin at two dose concentrations in rats. Q-D combined with either cefemandole or cefepime.

ExcerptReferenceRelevance
"To assess the possibility that non-aminoglycoside antibiotics may adversely affect the nephrotoxicity of the new semisynthetic aminoglycoside netilmicin, we gave ampicillin, carbenicillin, methicillin, cefamandole, and clindamycin, either singly or in combination with netilmicin, at two dose concentrations in rats."( Nephrotoxicity of netilmicin in combination with non-aminoglycoside antibiotics.
Hagstrom, GL; Luft, FC; Maxwell, DR; Sloan, RS; Yum, MN, 1978
)
0.45
" Tobramycin was the most effective aminoglycoside when used in combination with beta-lactam antibiotics."( In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens.
Bartlett, M; Crane, JK; Griffin, PS; Miller, MA; Yousuf, M, 1979
)
0.58
"Amdinocillin alone and in combination with other beta-lactam antibiotics was tested for in vitro activity against aminoglycoside-susceptible and resistant gram-negative bacteria."( In vitro activity of amdinocillin in combination with other beta-lactam antibiotics against aminoglycoside-susceptible and resistant gram-negative bacteria.
Gibson, G; Nachamkin, I; Samel, C; Sawyer, K; Skalina, D, 1988
)
0.27
" The findings indicate that antibiotic disks used routinely in the clinical laboratory can be used in a simple elution test to determine susceptibility of organisms to beta-lactam antibiotics alone and in combination with amdinocillin."( Collaborative clinical laboratory study of a broth-disk test for determination of bacterial susceptibility to beta-lactams in combination with amdinocillin.
Barry, AL; Beskid, G; Cleeland, R; Fallat, V; Isenberg, HD; Murray, PR; Pierson, C; Squires, E; Tilton, RC, 1987
)
0.27
"Ninety-four cases of pyelonephritis including 20 who had concurrent bacteremia were treated with cefamandole alone or in combination with either gentamicin or tobramycin."( Cefamandole alone and combined with gentamicin or tobramycin in the treatment of acute pyelonephritis.
Gentry, LO; Martin, MD; Smythe, J; Wood, BA, 1980
)
1.92
", (iv) Q-D combined with either cefamandole or cefepime."( Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.
Entenza, JM; Féger, C; Glauser, MP; Moreillon, P; Vouillamoz, J, 2000
)
0.59
"125 x MIC) combined with vancomycin (0."( In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus.
Bergeret, M; Raymond, J, 1999
)
0.56
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

The bioavailability of cefoperazone and cefamandole (20mg/kg) were investigated in dogs. The findings related to minimal inhibitory concentrations (MICs) for 90 bacterial strains isolated clinically from dogs.

ExcerptReferenceRelevance
" The sparingly soluble ester is shown to be well absorbed orally by mice, but only when administered in solution in a partially non-aqueous vehicle, 50% propylene glycol."( Orally active esters of cephalosporin antibiotics. II. Synthesis and biological properties of the acetoxymethyl ester of cefamandole.
Finley, DR; Frogge, JA; Line, VD; Wheeler, WJ; Wright, WE, 1979
)
0.47
"Three different intramuscular formulations of cefonicid (a new long acting cephalosporin) have been tested for bioavailability in 12 healthy volunteers, using a triple crossover design."( Bioavailability in human volunteers of three intramuscular formulations of cefonicid: a long-acting cephalosporin.
Brumfitt, W; Grady, D; Hamilton-Miller, JM; James, I; Price, C,
)
0.13
"The bioavailability of parental cefamandole, nafate, a new cephalosporin antibiotic, was evaluated with respect to the effects of a lidocaine diluent on its tolerability and absorption after intramuscular administration."( Bioavailability and pain study of cefamandole nafate.
Coonrod, JD; Foster, TS; Shrewsbury, RP,
)
0.69
") bioavailability of cefoperazone and cefamandole (20mg/kg) were investigated in dogs and the findings related to minimal inhibitory concentrations (MICs) for 90 bacterial strains isolated clinically from dogs."( Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration.
Anfossi, P; Carli, S; Montesissa, C; Villa, R; Zanoni, R, 2003
)
0.83
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33

Dosage Studied

Cefamandole is required to maintain adequate serum and tissue levels for operations lasting longer than 4 or 6 hours in which standard or pulsatile CPB are used. Ceftizoxime at a dosage of 1 gm twice daily proved to be at least as effective as 1gm.

ExcerptRelevanceReference
" When cefazolin, which was less irritating than cefamandole by the subconjunctival route, was given in a dosage of 100 mg, levels in ocular tissues were increased by twofold to fourfold and in aqueous humor by 15-fold, compared to the concentrations produced by the 12."( Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits.
Barza, M; Baum, JL; Kane, A, 1979
)
0.83
" Further studies demonstrated that significant blood and urine levels of 1 were not obtained after dosing 2a, 2b, and 2f orally at 17 mg/kg in mice."( Orally active esters of cephalosporin antibiotics. 3. Synthesis and biological properties of aminoacyloxymethyl esters of 7-[D(-)-mandelamido]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-3-cephem-4-carboxylic acid.
Howard, DP; Huffman, GW; Osborne, HE; Preston, DA; Wheeler, WJ; Wright, WE, 1979
)
0.26
" This relationship was used to calculate the loading dose (LD), maintenance doses (D), and dosage intervals (tau) with regard to renal function."( Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
Brogard, JM; Grudet, O; Kopferschmitt, J; Lavillaureix, J; Spach, MO, 1979
)
1.7
" A dosage regimen of multiple doses is established as a function of the pharmacokinetic parameters of the antibiotic for patients with terminal renal impairment undergoing periodic sessions of hemodialysis."( Pharmacokinetics of cefamandole in patients undergoing hemodialysis.
Campillo, JA; Dominguez-Gil, A; Lanao, JM; Rubio, F; Tabernero, JM, 1979
)
0.58
" The dosage was 80."( [Laboratory and clinical studies of cefamandole in children (author's transl)].
Futamura, J; Iwai, N; Miyazu, M; Osuga, T; Sasaki, A, 1979
)
0.53
" Dosage varied between 1 and 2 g given intravenously every 6 hr."( Cefamandole in treatment of peritonitis.
Geheber, CE; Guest, BS; Kolb, LD; Stone, HH, 1978
)
1.7
" A dosage of 37 mg/kg administered intravenously at 6-h intervals provided a serum concentration in excess of the minimum inhibitory concentrations of common bacterial pathogens for 4 h, and in young infants for 5 h, after dosing."( Pharmacokinetics of cefamandole in infants and children.
Gahol, VP; Walker, SH, 1978
)
0.58
" Guidelines for dosing and administration of vancomycin for cardiovascular surgical prophylaxis are provided."( Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial.
Acher, CW; Bohn, MJ; Kroncke, GM; Maki, DG; Myerowitz, PD; Stolz, SM, 1992
)
0.57
" We prospectively studied two different cefamandole dosing regimens in patients undergoing aortic aneurysm surgery (phase 1, 1 gm intravenously at the induction of anesthesia; phase 2, 2 gm intravenously at the induction of anesthesia followed by 1 gm intravenously every 2 hours during surgery)."( Cefamandole levels during thoracoabdominal aortic aneurysm surgery.
Coselli, JS; Crawford, ES; Cribari, C; Harris, RL; Jernigan, D; Safi, HJ; Yuk, JH, 1991
)
1.99
" Regional dosing was carried out at the start of the operation, following the application of a mid-thigh tourniquet, by administration into a foot vein."( Determination of bone and fat concentrations following systemic cefamandole and regional cefuroxime administration in patients undergoing knee arthroplasty.
Dixon, JH; Fernando, HC; Hoddinott, C; Lovering, AM; Reeves, DS, 1990
)
0.52
" Additional antibiotic dosing may be warranted prior to prosthesis insertion in these patients."( Altered pharmacokinetics of antibiotics during vascular surgery.
Carver, M; Goldstone, J; Guglielmo, BJ; Rodondi, LC; Salazar, TA; Stoney, RJ, 1989
)
0.28
" Intraoperative dosing of cefamandole is required to maintain adequate serum and tissue levels for operations lasting longer than 4 or 6 hours in which standard or pulsatile CPB, respectively, are used."( Cefamandole pharmacokinetics during standard and pulsatile cardiopulmonary bypass.
Cleveland, RJ; Faraci, PA; Melby, MJ; Shargel, L; Weiner, B, 1988
)
2.02
" It has no advantage over other cephalosporins with regard to spectrum of antibacterial activity, but has a longer half-life than other second generation cephalosporins, except cefonicid, and can be administered according to a twice daily dosage schedule."( Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Campoli-Richards, DM; Lackner, TE; Monk, JP, 1987
)
0.27
" The sustained plasma and bone levels achieved with ceforanide obviate the need for intraoperative dosing necessary with other agents."( Comparison of ceforanide and cephalothin prophylaxis in patients undergoing total joint arthroplasty.
Brause, BD; Hirsch, JC; Roberts, RB; Salvati, EA; Soave, R, 1986
)
0.27
" Dosage recommendations and clinical considerations for cefonicid use in continuous ambulatory peritoneal dialysis patients are discussed."( Peritoneal transport of cefonicid.
Curry, J; Deterding, J; Gal, P; Lane, T; Morse, GD; Nairn, DK, 1987
)
0.27
"3), indicating that there is no need to supplement a dosing regimen of cefamandole due to loss by dialysis."( Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.
Arnold, T; Bliss, M; Jones, W; Logan, J; Mayersohn, M; Michael, UF, 1986
)
0.81
" Since cefonicid concentrations were within the therapeutic range for nearly all dosing intervals, we conclude that the guidelines used for dosage reduction and interval prolongation in this study result in therapeutically adequate concentrations in serum and, at the same time, result in no significant drug accumulation."( Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function.
Conte, JE; Phelps, RT, 1986
)
0.27
" Dosage of cefonicid should be adjusted according to the degree of renal impairment."( Pharmacokinetics of cefonicid in uraemic patients.
Fillastre, JP; Fourtillan, JB; Humbert, G; Lefevre, MA; Leroy, A; Ramis, N; Reumont, G, 1986
)
0.27
" Mean wound drainage concentrations ranged between 10 and 12 micrograms/ml during a dosing interval and dropped to 7 micrograms/ml 12 hours after the last dose."( Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients.
Buchwald, H; Mann, HJ, 1986
)
1.71
" This study may partially explain the poor results obtained with single daily dosing of cefonicid in endocarditis."( Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.
Dudley, MN; Nightingale, CH; Quintiliani, R; Shyu, WC, 1986
)
0.27
" Smaller doses, longer dosing intervals and, potentially, a reduction in total drug cost may be the real advantage of these agents."( Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.
Polk, RE; Tartaglione, TA, 1985
)
0.27
" The recommended dosage regimens (i."( Clinical evaluation of cefotiam and cefamandole in respiratory tract infections.
Beumer, HM; Kahn, M; Olislagers, WP; van Hamersveld, JD, 1985
)
0.54
" A single dosage of doxycycline was as effective at preventing posthysterectomy pelvic infection as were multiple dosages of cefamandole."( Doxycycline and cefamandole prophylaxis for premenopausal women undergoing vaginal hysterectomy.
Hemsell, DL; Hemsell, PG; Nobles, BJ, 1985
)
0.82
" Ceftizoxime at a dosage of 1 gm twice daily proved to be at least as effective as 1 gm of cefamandole given four times daily."( Ceftizoxime treatment of cutaneous and subcutaneous tissue infections.
Layne, PP; Parish, LC; Parks, DB; Uri, JV, 1984
)
0.49
" Dosage for ceftizoxime was 1 gm."( Ceftizoxime in the treatment of urinary tract infections.
Crawford, ED; Plimpton, HW, 1982
)
0.26
" Based on available data, single daily dosing of cefonicid in the therapy of Staph."( Review of cefonicid, a long-acting cephalosporin.
Dudley, MN; Nightingale, CH; Quintiliani, R,
)
0.13
" Because of high blood levels and long serum half-life, daily dosing with cefonicid is feasible."( Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract.
Geckler, RW; Goodman, JS; McCormack, GD,
)
0.43
" Dosage schedules resulting in maintenance of antibiotic concentrations in serum high above the MIC seemed to correlate well with treatment success."( Treatment of typhoid fever with cefamandole.
Harakeh, H; Kantarjian, H; Nassar, NT; Talhouk, A; Uwaydah, M; Vartivarian, S, 1984
)
0.55
", for all of the cephalosporins except cefoperazone and cefotaxime, modification of dosage is necessary when renal insufficiency is present."( An overview of pharmacokinetics.
Cutler, RE,
)
0.13
" Cefonicid dosage can be reduced in proportion to decreases in creatinine clearance from normal levels."( Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.
Alexander, DP; Barriere, SL; Conte, JE; Gambertoglio, JG; Stagg, RJ,
)
0.13
" These kinetic parameters were used to formulate dosage regimens for patients with renal impairment."( Cefonicid kinetics in subjects with normal and impaired renal function.
Blair, AD; Cutler, RE; Forland, SC; Jacob, L; Maxwell, BM, 1984
)
0.27
" The elimination half-life of ceforanide is about 3 hrs in patients with normal renal function; this allows twice daily dosing for the majority of patients."( Ceforanide: antibacterial activity, pharmacology, and clinical efficacy.
Barriere, SL; Mills, J,
)
0.13
" These pharmacokinetic observations support the current dosage recommendations for the use of cefoxitin in treating and preventing gynecologic infections, as well as the recommendation that it be administered shortly before the operation to maximize tissue levels during the perioperative period."( Serum and tissue concentrations of cefoxitin and cefamandole in women undergoing hysterectomy.
French, MA; Nightingale, CH; Quintiliani, R; Russo, JN, 1983
)
0.52
" We conclude that there is no place for a single preoperative dosage of cefamandole in the management of appendicitis."( A controlled study of single dosage cefamandole in the prophylaxis of wound infections in appendectomy.
Gledhill, T; Odurny, A; Weaver, PC, 1983
)
0.77
"Forty patients with suspected non-CNS Hib infections were treated with cefamandole at a dosage of 100 to 150 mg/kg/day."( The role of cefamandole in the treatment of Haemophilus influenzae infections in infants and children.
Azimi, PH; Chase, PA, 1981
)
0.87
" Intensive dosing schedules were employed to achieve maximal therapeutic benefits with short-term treatment."( Comparison of cefamandole, cephalothin, ampicillin, and chloramphenicol in experimental Escherichia coli meningitis.
Allen, JC; Beam, TR, 1980
)
0.62
" CMD was administered by one shot intravenous or drip infusion at a dosage of 100 approximately 135 mg/kg/day for 4 approximately 14 days."( [Laboratory and clinical studies of cefamandole in pediatric infections (author's transl)].
Kawamura, M; Maki, T; Takashima, Y; Tauchi, N; Uozumi, K, 1980
)
0.54
" Dosage recommendations for 1- to 2 year-old children are presented."( Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.
Bawdon, RE; Buckley, JA; Dajani, AS; Pfeffer, M; Smyth, RD; Thirumoorthi, MC; Van Harken, DR, 1982
)
0.26
" over a course of 5 days; dosage interval 12 h, dosages 1000, 2000, 3000, and 5000 mg/kg per day, respectively."( [Experimental studies in animals on the nephrotoxicity of some new cephalosporin antibiotics: cefamandole, EMD 29 645, and 29 946 (author's transl)].
Beck, H; Nierhoff, N; Sack, K, 1980
)
0.48
" Dosing recommendations for patients with renal insufficiency are provided."( Ceforanide kinetics in renal insufficiency.
Alford, RH; Hawkins, SS; Pfeffer, M; Smyth, RD; Stone, WJ, 1981
)
0.26
" Dosage and side effect information, in particular, cannot be reliably extrapolated from data derived from studies in adults."( The position of the pharmaceutical industry in the development of drugs for pediatric use.
Christensen, CN, 1980
)
0.26
" The slower elimination kinetics of ceforanide are indicative of the potential for a longer dosing interval and more effective antibiotic therapy as compared with available cephalosporins."( Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
Hottendorf, GH; Lee, FH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1980
)
0.26
" In this latter group, otitis media was induced by injecting glycerin into the middle ear clefts 1 months after birth, and the degree of inflammation was varied by administering or withholding antibiotics (cefamandole and dibekacin) and adjusting the dosage regimen."( The relationship between the degree of chronic middle ear inflammation and tympanic bulla pneumatization in the pig as animal model.
Ikarashi, F; Nakano, Y; Okura, T, 1994
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)IC50 (µMol)450.00000.50000.50000.5000AID681363
Solute carrier family 15 member 1Homo sapiens (human)Ki8,100.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki2,809.18990.79434.22108.0000AID612540
Solute carrier family 22 member 6Homo sapiens (human)Ki0.03000.03003.20437.8200AID681377
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki2,800.00003.00006.47788.5000AID681114
Solute carrier family 22 member 8Homo sapiens (human)Ki0.04600.04004.22979.0000AID681373
Solute carrier family 22 member 11Homo sapiens (human)Ki1.14000.20002.57716.1500AID681569
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)IC50 (µMol)90.00006.03006.03006.0300AID681344
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 7Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 7Homo sapiens (human)
organic anion transportSolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 7Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 7Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
cytosolSolute carrier family 22 member 7Homo sapiens (human)
plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
membraneSolute carrier family 22 member 7Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (154)

Assay IDTitleYearJournalArticle
AID576966Antimicrobial activity against coagulase-negative Staphylococcus isolated from human preoperative skin by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1124331Antibacterial activity against Serratia marcescens ATCC 138801979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID561957Antibacterial activity against methicillin-susceptible and beta-lactamase-producing Staphylococcus aureus Type C using 5x10'7 CFU/ml high inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID1133985Antimicrobial activity against Aerobacter 2828 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID524393Antibacterial activity against Escherichia coli NKE1359 harboring deletion mutation in acrB protein and plasmid expressing BADnlpE gene in presence of increasing concentration of arabinose2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID576977Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 50 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID524262Antibacterial activity against Escherichia coli NKE155 harboring deletion mutation in acrB protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID561954Antibacterial activity against methicillin-susceptible and beta-lactamase-producing Staphylococcus aureus Type B using 5x10'5 CFU/ml standard inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID524264Antibacterial activity against Escherichia coli NKE158 harboring deletion mutation in acrB protein and vector expressing cpxAR gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID558318Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1133978Antimicrobial activity against Streptococcus pyogenes 3124 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID558319Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558781Antibacterial activity against acrB-deficient Salmonella enterica NKS422 harboring acrEF gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID561952Antibacterial activity against methicillin-susceptible and beta-lactamase-producing Staphylococcus aureus Type A TX01117 using 5x10'5 CFU/ml standard inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID1133990Antimicrobial activity against Proteus mirabilis 2830 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1124323Antibacterial activity against beta-lactamase producing Staphylococcus aureus C-141979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID577001Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 1000 mg/litre at ambient temperature of 30 to 45 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID576974Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 50 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID524260Antibacterial activity against Escherichia coli NKE96 harboring deletion mutation in acrB protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID125055Plasma half-life in monkey after intravenous administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID560224Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing stm3031 gene deletion mutant by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID576976Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 500 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1211833Total biliary clearance in iv dosed human after 6 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID576969Antimicrobial activity against coagulase-negative Staphylococcus isolated from human prosthetic joint infection site by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID558778Antibacterial activity against tolC-deficient Salmonella enterica NKS174 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID524265Antibacterial activity against Escherichia coli NKE159 harboring deletion mutation in acrB, cpxAR protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID576971Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 50 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID561953Antibacterial activity against methicillin-susceptible and beta-lactamase-producing Staphylococcus aureus Type A TX01117 using 5x10'7 CFU/ml high inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1219874Inhibition of recombinant human ABCC3 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID1133986Antimicrobial activity against Pseudomonas by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID1124332Antibacterial activity against Pseudomonas aeruginosa 241979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID524391Antibacterial activity against Escherichia coli NKE1368 harboring deletion mutation in acrB, acrD and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524386Antibacterial activity against Escherichia coli NKE157 harboring deletion mutation in acrB, acrD protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1211879Unbound biliary clearance in iv dosed Wistar rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID558777Antibacterial activity against acrB-deficient Salmonella enterica NKS291 harboring hns gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1211814Drug excretion in iv dosed human assessed as compound excreted into bile after 6 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID561959Antibacterial activity against methicillin-susceptible and beta-lactamase-negative Staphylococcus aureus ATCC 25923 using 5x10'7 CFU/ml high inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID561955Antibacterial activity against methicillin-susceptible and beta-lactamase-producing Staphylococcus aureus Type B using 5x10'7 CFU/ml high inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID576963Antimicrobial activity against Staphylococcus aureus ATCC 29213 administered as powder at 45 degC after 24 hrs2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1219875Inhibition of recombinant human ABCC4 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID1133982Antimicrobial activity against Enterobacter 2902 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID1133984Antimicrobial activity against Aerobacter 2826 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID561958Antibacterial activity against methicillin-susceptible and beta-lactamase-negative Staphylococcus aureus ATCC 25923 using 5x10'5 CFU/ml standard inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID1133979Antimicrobial activity against Enterococcus 2862 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID576967Antimicrobial activity against Staphylococcus aureus isolated from human preoperative skin by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID193758Plasma half-life in rats after intravenous administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID576975Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 100 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID561956Antibacterial activity against methicillin-susceptible and beta-lactamase-producing Staphylococcus aureus Type C using 5x10'5 CFU/ml standard inoculum after 24 hrs by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
AID678797TP_TRANSPORTER: inhibition of PGF2alpha in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID524382Antibacterial activity against Escherichia coli NKE160 harboring deletion mutation in acrB protein and vector expressing tolC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1124327Antibacterial activity against beta-lactamase producing Klebsiella pneumoniae 3631979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID576978Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 100 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID91061Plasma half-life in human after intravenous administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID678819TP_TRANSPORTER: inhibition of PGF2alpha in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID524390Antibacterial activity against Escherichia coli NKE1316 harboring deletion mutation in acrB, acrD and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524387Antibacterial activity against Escherichia coli NKE1365 harboring deletion mutation in acrB and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524261Antibacterial activity against Escherichia coli NKE154 harboring vector expressing acrB deletion mutant2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1124322Antibacterial activity against Staphylococcus aureus 209P JC-11979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1133983Antimicrobial activity against Serratia 2852 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID524392Antibacterial activity against Escherichia coli NKE1369 harboring deletion mutation in acrB, acrD, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID681373TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID524388Antibacterial activity against Escherichia coli NKE1366 harboring deletion mutation in acrB and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681344TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID1124329Antibacterial activity against Proteus vulgaris CN-3291979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID560222Antibacterial activity against Salmonella enterica serovar Typhimurium 01-4 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID558776Antibacterial activity against acrB-deficient Salmonella enterica NKS175 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID558782Antibacterial activity against acrB-deficient Salmonella enterica NKS416 harboring acrEF, hns gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID495629Antimicrobial activity against Pseudomonas luteola by disk diffusion method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1124328Antibacterial activity against Proteus mirabilis PR-41979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID576999Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 500 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1124324Antibacterial activity against Streptococcus pneumoniae I1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID1133977Antimicrobial activity against Staphylococcus aureus 2865 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID524266Antibacterial activity against Escherichia coli NKE128 harboring deletion mutation in acrB and tolC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1133989Antimicrobial activity against Proteus morganii 2834 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID524383Antibacterial activity against Escherichia coli NKE161 harboring deletion mutation in acrB protein, vector expressing tolC gene and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID576968Antimicrobial activity against Staphylococcus aureus isolated from human prosthetic joint infection site by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID558780Antibacterial activity against acrEF-deficient Salmonella enterica NKS176 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID681569TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT4-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID1211853Unbound biliary clearance in iv dosed human after 6 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID524389Antibacterial activity against Escherichia coli NKE1367 harboring deletion mutation in acrB, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1211871Total biliary clearance in iv dosed Wistar rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1133988Antimicrobial activity against Proteus vulgaris 2829 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID524384Antibacterial activity against Escherichia coli NKE126 harboring deletion mutation in acrB and acrD protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1124326Antibacterial activity against Klebsiella pneumoniae1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID576964Antimicrobial activity against Staphylococcus aureus ATCC 29213 by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1124325Antibacterial activity against Escherichia coli NIHJ JC-21979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID681363TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002Life sciences, Mar-08, Volume: 70, Issue:16
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.
AID1133987Antimicrobial activity against Providencia 2851 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID681789TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Cefamandole: 2000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2
The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
AID1219873Inhibition of recombinant human ABCC2 expressed in insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID524394Antibacterial activity against Escherichia coli NKE1355 harboring deletion mutation in acrB protein and plasmid expressing BAD gene in presence of increasing concentration of arabinose2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1124330Antibacterial activity against Enterobacter cloacae 2331979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its relate
AID576962Antimicrobial activity against Staphylococcus epidermidis DSM3269 by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1211803Drug excretion in iv dosed Wistar rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1133981Antimicrobial activity against Escherichia coli 2884 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID576970Antimicrobial activity against Staphylococcus epidermidis isolate OR1 treated in solution at 45 degC after 24 hrs2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID576973Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 500 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID577000Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 500 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID660262Ratio of MIC for wild type Escherichia coli TG1 to MIC for acrB-deficient Escherichia coli KAM3 by two-fold serial dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID524263Antibacterial activity against Escherichia coli NKE127 harboring deletion mutation in acrB and cpxAR protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID576979Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 500 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID558779Antibacterial activity against tolC-deficient Salmonella enterica NKS419 harboring hns gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID681377TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2002European journal of pharmacology, Mar-08, Volume: 438, Issue:3
Interaction of human organic anion transporters with various cephalosporin antibiotics.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID576995Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 100 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID558775Antibacterial activity against Salmonella enterica ATCC 14028 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1133980Antimicrobial activity against Klebsiella 2882 by agar dilution method1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.
AID524385Antibacterial activity against Escherichia coli NKE156 harboring deletion mutation in acrB protein and vector expressing acrD gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID576965Antimicrobial activity against Staphylococcus epidermidis isolate KO8 isolated from healthy human skin by disk diffusion method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID560223Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing Outer membrane protein STM3031 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID576972Antimicrobial activity against Staphylococcus isolates biofilms assessed as change in optical density ratio of biofilms at 100 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (930)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990763 (82.04)18.7374
1990's99 (10.65)18.2507
2000's47 (5.05)29.6817
2010's20 (2.15)24.3611
2020's1 (0.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.67 (24.57)
Research Supply Index7.14 (2.92)
Research Growth Index4.02 (4.65)
Search Engine Demand Index71.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials235 (22.84%)5.53%
Reviews29 (2.82%)6.00%
Case Studies65 (6.32%)4.05%
Observational2 (0.19%)0.25%
Other698 (67.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Population Pharmacokinetics of Cephalosporins and Macrolides in Children With Community Acquired Pneumonia [NCT02775968]750 participants (Anticipated)Observational2017-06-21Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]